Illustrative image.

KIMMTRAK

Name: KIMMTRAK
Brand: Immunocore
Availability: InStock

Tebentafusp-tebn

Prescription required

$95980.00

100MCG/0.5 · 4 × 1 · 1 month supply

BrandBranded medicine· By Immunocore

$95980.00 per month

How long a supply?

1 month$95980.00 a monthOne-off$95980.00

Supplied from Israel

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Annual cost

$1247740a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningCytokine release syndrome

BOXED WARNING: CYTOKINE RELEASE SYNDROME

Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated [(see Dosage and Administration, see Warnings and Precautions ].

Read this with the rest of the clinical information

About KIMMTRAK

Overview

KIMMTRAK contains tebentafusp-tebn and is given by intravenous infusion. It treats adults who are HLA-A*02:01-positive and have uveal melanoma, a type of eye cancer, that cannot be removed by surgery or has spread to other parts of the body. It works by binding to a specific target on melanoma cells and engaging T cells, helping these immune cells destroy the cancer cells.

What it treats

Uveal melanoma that cannot be removed by surgery or has spread to other parts of the body, in adults who are HLA-A*02:01-positive.

Safety information

Side effects

Common side effects include cytokine release syndrome, rash, fever, itching, tiredness, nausea, chills, abdominal pain, swelling, low blood pressure, dry skin, headache and vomiting. Common blood test changes include lower lymphocyte counts (a type of white blood cell), increased creatinine, increased blood sugar, increased liver enzymes, lower hemoglobin and lower phosphate. Serious side effects that warrant contacting your doctor include cytokine release syndrome, skin reactions such as rash, itching or skin swelling, and elevated liver enzymes. Your doctor should monitor liver enzymes and bilirubin with blood tests. KIMMTRAK may harm an unborn baby. Patients who could become pregnant should use effective contraception.

FDA boxed warning

Cytokine release syndrome

BOXED WARNING: CYTOKINE RELEASE SYNDROME

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for fever, chills or low blood pressure. KIMMTRAK can cause serious or life-threatening cytokine release syndrome. - Seek immediate medical attention for a severe rash, severe itching or swelling of the skin.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The label lists no contraindications for KIMMTRAK. KIMMTRAK may cause harm to an unborn baby. Patients who could become pregnant should be advised of this risk and use effective contraception. Skin reactions, including rash, itching and swelling, can occur and require treatment based on their severity and persistence. Liver enzymes may also rise; ALT, AST and total bilirubin should be monitored.

Using KIMMTRAK

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label KIMMTRAK (TEBENTAFUSP) INJECTION, SOLUTION, CONCENTRATE [IMMUNOCORE COMMERCIAL LLC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.